{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"25"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"will be tabulated after the completion of cycle four and cycle eight (for those who would have completed 8 cycles), and the overall response rate for the entire population after up to eight cycles will be estimated and compared to the responses reported in the phase II study by Richardson et al. using the 3-drug-combination.","groups":[{"description":"This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.\n\nBortezomib: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\\^2, days 1, 8, 15 and 22\n\nDexamethasone: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).\n\nLenalidomide: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression","id":"OG000","title":"Patients With Multiple Myeloma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to eight cycles of treatment, up to 9 months","title":"Response","type":"SECONDARY","unitOfMeasure":"Participants"}